FDA approves first generics of Gilenya

FDA

5 December 2019 - The U.S. FDA has approved three applications for first generics of Gilenya (fingolimod) capsules for the treatment of relapsing forms of multiple sclerosis in adult patients.

“Approving safe and effective generics so patients have more treatment options continues to be a priority for the FDA,” said Janet Woodcock, M.D., director of the FDA’s Center for Drug Evaluation and Research. 

“Having access to affordable treatments is important for patients with conditions that require ongoing care. The FDA has a longstanding commitment to increasing patient access to lower-cost, high-quality generic medicines.”

Read FDA press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Outcome , Medicine , US , Generic medicine